LNP Applications Highlight: A Cleverly Designed Nanosystem: Targeted Retention, Controlled Visual Drug Release, and Cascade Amplification Therapy for Mammary Carcinoma in vitro

Posted on July 21, 2021

Theranostic Medicine Infographic

The advancement of nanoparticle technology has made possible the early diagnosis and image-guided treatment of diseases. Nanoparticle systems can be used to monitor bioaccumulation sites and evaluate their therapeutic effectiveness all at once. This particular research study claims that nanoparticles combined with ultrasound and other molecular biology techniques can offer the ability to diagnose, visualize, and treat various diseases.

Liposomes are highly effective and efficient drug carriers. They are capable of passively targeting tumor cells with a high LDL receptor content. Not only are they efficient carriers, but once they have done their job they are easily biodegradable. Sonodynamic therapy (SDT) uses low-intensity focused ultrasound (LIFU) and sonosensitizer agents to cause physicochemical changes in cell structure. Several studies have shown this method to be effective on tumor cell lines with little or no toxic side effects. Conventional chemotherapeutics have poor results when using SDT due to the hypoxic environment created during SDT. However, the utility of this hypoxic environment can be exploited using pro-drugs which can be stimulated by hypoxia. AQ4N is one such drug. This aromatic bioreductive prodrug with no toxicity in healthy cells produces tumor-cytotoxic products, AQ4 and AQ4M, in a hypoxic environment. AQ4N is also the only topoisomerase II inhibitor that inhibits cell proliferation and promotes apoptosis that is currently available.

With this information, researchers from the Chongqing Medical University set out to prepare a lipid nanoparticle that would encapsulate a liquid-gas phase change material and the water-soluble prodrug AQ4N. They decided to link the surface of the LNP with the polypeptide C-RGD which can actively target 4T1 cells.

When using the LNP system in conjunction with LIFU, targeted release of the drug was achieved. They also showed that imaging of the process was effective when using photoacoustic (PA) and contrast-enhanced ultrasound (CEUS). Thus, the system was able to achieve both diagnosis and treatment through targeted drug delivery and therapy. In the future, this treatment could become a favorable anti-cancer treatment method. To read the full article click HERE!

This is just another example of how Avanti’s lipid products are impacting drug delivery technology! As a leader in lipid-based drug delivery solutions, we can help you with your drug delivery research. Visit our new LNP Technology page today, and find out how we can help!